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Abstract  26 
Purpose: The thiopurines azathioprine and 6-mercaptopurine are frequently used for remission maintenance 27 
in patients with inflammatory bowel diseases. However, there are therapy failures, and it is unclear whether 28 
clinical and laboratory parameters can be used to predict thiopurine metabolite concentrations (as a surrogate 29 
for adequate remission maintenance therapy) and clinical outcome in these patients.  30 
Methods: In this retrospective analysis of clinical routine patient data multivariate statistical models based 31 
on Linear Mixed Models regression and Generalized Estimating Equations logistic regression were 32 
developed. The adequacy of the models was assessed using Pearson’s correlation and a receiver operating 33 
characteristic curve. 34 
Results: This study included 273 patients and 1158 thiopurine metabolite measurements as well as routine 35 
laboratory and clinical data. In the statistical models, thiopurine metabolite concentrations and the odds of 36 
non-remission based on different clinical and laboratory parameters were computed. Correlation (r2) between 37 
predicted and measured thiopurine metabolites were 0.40 (p<0.001) for 6-thioguanine nucleotides and 0.53 38 
(p<0.001) for 6-methyl-mercaptopurine nucleotides, respectively. The model for remission classified data 39 
sets in remission and non-remission with a sensitivity of 63% and a specificity of 73%. The area under the 40 
receiver operating characteristic curve of the model was 0.72. 41 
Conclusions: Although the models are not yet accurate enough to be used in clinical routine, model-based 42 
prediction of thiopurine metabolite concentrations and of outcome is feasible. Until more accurate models 43 
are developed and validated, traditional therapeutic drug monitoring of thiopurine metabolites in patients 44 




The therapy with thiopurines such as 6-mercaptopurine (MP) and azathioprine (AZA) has become standard 47 
in patients with inflammatory bowel diseases (IBD).[1] Weight adapted dosing in mg/kg body weight is 48 
unreliable in adjusting sufficient blood concentrations because of a weak dose-effect relationship and high 49 
inter-individual variability of thiopurine pharmacokinetics, namely metabolism.[2] Therefore, the 50 
quantification of two thiopurine metabolites in blood has been proposed to optimize thiopurine treatment.[3] 51 
While high 6-thioguanine nucleotide (TGN) concentrations are responsible for therapeutic effects and 52 
myelotoxicity, the 6-methyl-mercaptopurine nucleotides (MMP) cause hepatotoxicity, but no therapeutic 53 
effect.[2, 4]   54 
The most important enzyme in the competing pathways of thiopurine metabolism is thiopurine-S-55 
methyltransferase (TPMT). Its inter-individual variation in activity is mainly based on polymorphisms of the 56 
TPMT gene.[5] Since the TPMT phenotype has an impact on the thiopurine metabolism, its screening prior 57 
to the start of the thiopurine therapy has been suggested.[2, 6-10] In clinical practice, additional TPMT 58 
genotyping to detect specific mutations is recommended if the TPMT enzyme activity is below 35 MTG/g 59 
Hb/h.[11, 12]  60 
The goal of therapeutic drug monitoring (TDM) is to ensure therapeutic response and reduce adverse drug 61 
events (ADE) by keeping concentrations within a predefined range. There is a broad consent that too high or 62 
too low TGN concentrations should be avoided, but the exact figure of both threshold values, and even if 63 
such rigid threshold values should be generally used at all, is controversially discussed and remains 64 
unclear.[1]  65 
While most studies support TDM[1, 5, 13-15], and two meta-analyses[16, 17] have shown associations 66 
between TGN concentrations and clinical outcome, some studies found no advantage of TDM-based dosing 67 
compared to a weight-based dosing scheme[18, 19], and Waljee et al.[20] claim that algorithms using age 68 
and laboratory values outperform TGN metabolite measurements in predicting clinical response by accuracy 69 
and costs. Since TDM is relatively time and work intensive, it would be worthwhile to support, or replace, 70 
TDM by other approaches. Several surrogates for TGN concentrations have been proposed, but their clinical 71 
utility remained limited.[21-24] Therefore, we performed a retrospective data analysis to assess and quantify 72 
the predictive value of different clinical and laboratory parameters on the thiopurine metabolite 73 
concentrations and the clinical outcome.  74 
 75 
Material and methods 76 
Data of all thiopurine metabolite quantifications, which were carried out at the University Hospital of 77 
Zurich (USZ) and interpreted by the Department of Clinical Pharmacology and Toxicology between 78 
01.01.2003 and 30.11.2015, formed the retrospective data set for this study. Data were extracted 79 
retrospectively using the USZ patient record database KISIM V.4.933 (Cistec AG, Zurich, Switzerland). 80 
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Inclusion criteria for patients were a diagnosis of IBD (Crohn’s disease, ulcerative colitis, indeterminate 81 
colitis) and at least one thiopurine metabolite quantification at the USZ in the mentioned time frame. 82 
Exclusion criteria were a documented refusal of the patient to use his or her data for research purposes and 83 
insufficient clinical data. Patient characteristics and clinical parameters such as age, sex, smoking status, 84 
BMI, diagnosis, TPMT genotype, TPMT phenotype, IBD concerning co-medication as well as dose, type 85 
of thiopurine given (AZA, MP, thioguanine) were documented for each metabolite measurement as far as 86 
available. Additionally, the MMP/TGN ratio was calculated. A patient with TPMT activity below 35 87 
MTG/g Hb/h was defined as low enzyme activity phenotype, one with equal or higher activity was defined 88 
as intermediate/high enzyme activity phenotype. Also, laboratory parameters prior to or at the moment of 89 
metabolite measurement were gathered. The data set contained information about hemoglobin (Hb), mean 90 
cellular volume (MCV), platelets, leukocytes, lymphocytes, creatinine, total bilirubin (hereinafter referred 91 
to as bilirubin), albumin, transaminases, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase 92 
(GGT), c-reactive protein (CRP), prothrombin time (PT), and calprotectine. The study was approved by the 93 
Ethics Committee of the Canton of Zurich (BASEC-Nr. 2017-02317) and carried out respecting all 94 
pertinent laws and regulations in force in Switzerland at the time of data collection. The clinical outcome 95 
forms the dependent binary variable of the logistic regression and was therefore categorised in the two 96 
characteristics “remission” and “non-remission”, whereas “remission” is used synonymously with 97 
(therapeutic) response and “non-remission” with non-response, respectively. The classification of the 98 
clinical outcome was mainly based on the documented global assessment of the treating physician. If such 99 
an information was not available, the following criteria defined the classification. Patients were classified 100 
as responders, if they did not suffer from a stool frequency higher than two solid defecations per day or no 101 
change in treatment was described. As soon as patients suffered from a poor general condition related to the 102 
IBD, blood in stool or more than two fluid defecations, they were classified as non-responders.  103 
For the metabolite measurements, the quantification method used at the Department of Clinical Chemistry 104 
of the University Hospital of Zurich was changed during the study period. The high performance liquid 105 
chromatography with ultraviolet detection (HPLC-UV),[25, 26] which was used until 06.05.2011 has been 106 
replaced by a liquid chromatography–mass spectrometry (LC-MS) quantification method, which has been 107 
developed at the USZ based on the work of Dervieux et al.[27] Both fully validated methods have been 108 
compared and they have been completely consistent. Statistical analysis was performed using IBM SPSS 109 
Statistics 22 (International Business Machines Corp. Armonk, NY, USA). We used frequencies, means, 110 
median, standard deviation σ, minimum, maximum and Inter Quartile Range (IQR) for descriptive 111 
statistics. The following continuous predictors violated the normal distribution assumption (tested by visual 112 
assessment with boxplot diagrams) and were therefore transformed to their natural logarithm ln(y) for all 113 
analyses: creatinine, bilirubin, AST, ALT, GGT, ALP, CRP, leukocytes, lymphocytes, calprotectin, TGN, 114 
MMP, MMP/TGN. Multiple observations per patient in our data implied clustered data, therefore Linear 115 
Mixed Models Regression and Generalized Estimating Equations (GEE) logistic regression were used for 116 




To analyse the impact of a single predictor on ln(TGN) and ln(MMP), we used Linear Mixed Models with 119 
one predictor. To elicit the statistical model predicting the TGN and MMP concentrations best, Multiple 120 
Linear Mixed Models were used. The multiple Linear Mixed Model Regression is based on formula 1.  121 
 122 
F.1   …  123 
i: patient number, i = [1, …, 273], j: observation number within patient i, j = [1, …, ni], k: predictor 124 
number k = [1, …, K], yij; dependent variable, xkij; predictor, a: regression coefficient, intercept, bk: 125 
regression coefficient, slope, rij: residuum, ui: random effect, e: Euler’s number, mathematical constant, 126 
e≈2.718 127 
 128 
To analyse the impact of a single parameter on binary clinical outcome we used univariate GEE logistic 129 
regression with exchangeable correlation structure. To determine the statistical model predicting the binary 130 
clinical outcome we used multiple GEE logistic regression with exchangeable correlation structure. The 131 
univariate GEE logistic regression is based on formula 2. 132 
 133 
F.2   …  134 
i: observation number i, i = (1, …, 1158), πi: probability of non-response, k: predictor number k = (1, …, 135 
K), a: regression coefficient, intercept, bk: regression coefficient, slope, xki; predictor, e: Euler’s number, 136 
mathematical constant, e≈2.718 137 
 138 
The parameters of the final model were selected based on the following criteria. First, there had to be a 139 
significant (p<0.05) effect in the univariate analysis. Second, if a parameter had a significant effect, which 140 
was in its characteristics clearly not compatible with current knowledge of physiology, that parameter was 141 
not included in the model, assuming that an error of the first kind occurred. Different models for each 142 
question were evaluated using both Akaike Information Criterion (AIC) and Bayesian Information 143 
Criterion (BIC) for Linear Mixed Models and the Quasi-likelihood under the independence model Criterion 144 
(QIC) for GEE, respectively. Smaller information criterion values indicated statistically better fitting 145 
models. Two-sided tests were considered significant when p-value was <0.05. The accuracy and clinical 146 
applicability of the statistical models was reviewed by comparing the measured and predicted endpoints of 147 
all observations using Pearson’s correlation. The performance of the statistical model as binary classifier in 148 
response/non-response was tested using a receiver operating characteristic (ROC) curve and calculating the 149 
area under receiver operating characteristic curve (AUROC). The determination of the cut-off point was 150 
based on the highest Youden's J statistic (maximized sensitivity and specificity). It was determined under 151 




Results  154 
Patients and Observations. Thiopurine metabolite quantifications were available in 372 patients. Ninety-155 
nine patients were excluded because they either had no IBD diagnosis or sufficient clinical data was not 156 
available. A total of 273 patients was hence included in this study. Within this population, 40% of the patients 157 
were female. 58% of the patients had Crohn’s disease, 42% had ulcerative colitis and one patient (<1%) had 158 
an indeterminate colitis. Demographics and laboratory values are shown in table 1 and supplementary table 159 
1. 4% of the patients in which TPMT genotyping was performed (n=136) had a mutation in the TPMT gen. 160 
Descriptive statistics of the TPMT phenotyping (activity measurements) is shown in table 1. Genotype and 161 
phenotype were discordant in 3 patients (2% of the 135 patients in which both genotype and TPMT activity 162 
were investigated). A total of 1158 metabolite measurements (observations) were performed for the 273 163 
patients in this study (mean: 4.2 observations per patient, range 1 - 29). In 53% of the observations, patients 164 
were non-smokers. The patients were treated with azathioprine in 80% of the observations, followed by 165 
mercaptopurine (18%) and thioguanine (2%). In 0.5% of the observations, the treatment was stopped by the 166 
patient prior to the metabolite measurement. In 61% of the observations, patients were treated with at least 167 
one comedication against IBD (corticosteroids, mesalazine, allopurinol, monoclonal antibodies inhibiting 168 
tumor necrosis factor, calcineurin inhibitors). In 11% of the observations, patients did not take any IBD-169 
related comedication at that time point, and information on comedication was not available in 27% of the 170 
observations (supplementary table 1). In 69% of the observations, patients were in remission.  171 
Final Statistical Models. The final adjusted coefficient estimates of the two selected models to predict the 172 
ln(TGN) and the ln(MMP) including the information criterion (IC) values are shown in table 2. The adjusted 173 
coefficient estimates for the statistical models to predict the natural logarithm of the odds of non-remission 174 
including its QIC is shown in table 3. 175 
Formula 3-5 show how dependent variables can be predicted by the identified independent variables 176 
(predictors) using multivariate linear (F.3/F.4) and logistic (F.5) Mixed Models. The first model (F.3) is 177 
determined to predict the TGN concentration. The second model (F.4) is determined to predict the MMP 178 
concentration. Formula F.3 and F.4 are based on Formula F.1. The third model (F.5) is determined to predict 179 
the clinical outcome, expressed as the odds of non-remission. Formula F.5 is based on F.2. For reasons of 180 
clarity and comprehensibility, the parameter estimates in F.3-5 are rounded to one relevant decimal place. 181 
For more accurate results, parameter estimates shown in table 2 and 3 can be used. 182 
F.3 145 . . . . . .183 . . .  184 
F.4 3722 . . . . . . .185 .  186 
F.5 	 	 0.5 . . . . .  187 
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TGN: 6-thioguanine nucleotides, MMP: 6-methyl-mercaptopurine, BMI: Body-Mass-Index, Alb: Albumin, 188 
Bili: Bilirubin, AST: Aspartate transaminase, ALT: Alanine transaminase, ALP: Alkaline phosphatase, 189 
CRP: C-reactive protein, Hb: Hemoglobin, MCV: Mean cellular volume, Leuk: Leukocytes, Lymph: 190 
Lymphocytes, e: Euler’s number, mathematical constant, e≈2.718. All parameters are used in the units 191 
given in table 1.  192 
Review of statistical models. Both predicted logarithmically transformed metabolite concentrations were 193 
significantly, but weakly correlated with the corresponding measured metabolite concentrations. The 194 
correlation coefficient r2 of TGNs and MMPs was 0.40 and 0.53, respectively. P-value was smaller than 0.001 195 
in both analyses. Scatter plot diagrams are shown in figure 1.  196 
When comparing the outcome model performance with TGN, MMP and the MMP/TGN ratio, the model 197 
including TGN turned out to be best. The ROC curve of the best binary model for outcome is shown in figure 198 
2. The best cut-off point to differentiate between remission and non-remission is at the odds of 0.32 with a 199 
sensitivity of 63% and a specificity of 73%. The AUROC of the binary statistical model was 0.72. 200 
 201 
Discussion 202 
In this study, statistical models were developed which can be used to predict thiopurine metabolite 203 
concentrations and the clinical outcome in patients with inflammatory bowel diseases under thiopurine 204 
therapy, based on clinical and laboratory parameters. The first two statistical models estimate TGN and MMP 205 
concentrations separately, based on BMI, dose, ALT, AST, ALP, bilirubin, CRP, MCV, leukocytes and 206 
lymphocytes. The third statistical model estimates the odds of non-remission of a patient based on albumin, 207 
TGN concentration, CRP, leukocytes and ALP. Our results show that the predicted metabolite concentrations 208 
do correlate with the measured ones, but that there is still unexplained variability. The results also show that 209 
a classification in remission and non-remission based on laboratory parameters is possible and should be 210 
better than a mere by-chance classification. 211 
Until now, only few other studies have tried to predict thiopurine metabolite concentrations and clinical 212 
outcome with statistical models using clinical and routine laboratory data. Waljee et al.[20] developed 213 
machine learning algorithms which differentiated clinical responders from non-responders more accurately 214 
than TGN measurements alone (AUROC: 0.86 versus 0.59, p<0.001). In our study, the statistical model 215 
could differentiate non-responders from responders with an AUROC of 0.72, which corroborates the 216 
usefulness of a statistical model. In the publication by Waljee and coworkers, there was a great number of 217 
independent predictor variables, of which the neutrophil count, alkaline phosphatase, red cell distribution 218 
width, age and WBC count were the most important. The inclusion of TGN concentrations as an independent 219 
variable led to no significant improvement of the AUROC. While the red cell distribution width and the 220 
neutrophils were not gathered in our study, the results concerning ALP and WBC seem to be consistent. In 221 
our study, ALP and WBC were amongst the variables with the highest predictive value for the clinical 222 
outcome. While the predictive value of WBC for the clinical outcome was described earlier[13], the impact 223 
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of ALP has not been investigated in earlier studies. The results of Waljee et al. concerning age and TGN 224 
concentrations are inconsistent with our results. In our study, age had no significant predictive value on the 225 
clinical outcome, while TGN was amongst the stronger predictors. Gardiner et al. [28] showed that a reduced 226 
MMP/TGN ratio is associated with therapy response. In our study, the MMP/TGN ratio did not better predict 227 
the clinical outcome than the TGN concentration. Several parameters, especially MCV, WBC and 228 
lymphocytes have been proposed in different studies as surrogates for TGN concentration measurements.[21-229 
24, 29, 30] In our study, MCV, WBC and lymphocyte count had a statistically significant predictive value 230 
for TGN concentrations, but the effect sizes were too small and the prediction by each parameter alone was 231 
too inaccurate for clinical practice.  232 
Some inherent limitations of the present study may have mitigated the predictive power of the models. Since 233 
parameters like calprotectin (82% missing), prothrombin time (75% missing) and smoking status (40% 234 
missing) were missing in too many datasets, they could not be tested in the model development process. 235 
Other parameters which were missing in more than 20% of the observations were TPMT activity (38% 236 
missing), albumin (36% missing), bilirubin (28% missing) and AST (46% missing). An analysis of a 237 
subgroup with complete data to improve the predictive power of the model was abandoned due to too few 238 
suitable datasets. Secondly, the classification of the clinical outcome in remission and non-remission was 239 
based on a global assessment by the treating physician, or, if not available, on the criteria mentioned above. 240 
An objective disease activity score would have been useful, but the clinical data necessary for such scores 241 
was not available in a large part of our population. In 18% of the observations, too few information to assess 242 
the clinical outcome was available, which also impaired the validity of the statistical analysis. Thirdly, the 243 
co-medication (27% missing) was not part of the statistical model. For the logistic regression GEE, binary 244 
predictors were needed. Since the combinations of co-medication were highly variable concerning drugs, 245 
doses, times of intake, etc, we could not find an adequate solution to transform the complex co-medications 246 
into one or more binary predictors in a reasonable and clinically justifiable way. Fourthly, the assay to 247 
quantify the TGN concentrations [26], had been replaced during the observation period by another 248 
method.[27] Since complete consistency of the results has been tested and confirmed, the concern of some 249 
authors [17] that the missing standardisation of TGN assays is a reason for the heterogeneity of the results of 250 
association studies between TGN concentrations and clinical outcome should not be valid for our 251 
investigation. Lastly, the models generated in the present study have not been validated in an independent 252 
dataset of “test” patients.  253 
In this study, the prediction of metabolite concentrations and clinical outcome was based on a multitude of 254 
parameters to summarize clinical and laboratory influences and interdependencies in statistical prediction 255 
models. Equations as shown above have not been published before. We could show that each a set of different 256 
parameters have statistically significant predictive values for the thiopurine metabolite concentrations and 257 
for the clinical outcome. Often, the observed effects of individual parameters are small, and relevant changes 258 
in the thiopurine metabolite concentrations or the odds of non-remission occur only if the predictive 259 
parameters change considerably. However, an appreciable fraction of variability remains unexplained and 260 
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hence unpredicted. Therefore, the accuracy is probably not good enough for clinical applicability. 261 
Additionally, the models are not intuitive, especially because of the logarithmic transformation of laboratory 262 
and clinical data. That is why this study has no immediate practical implications.  263 
Conclusion. Statistical models were developed which allow predictions about the clinical outcome and the 264 
thiopurine metabolite concentrations. However, these predictions are still too inaccurate and too complex for 265 
direct incorporation into clinical practice, so that therapeutic drug monitoring in patients with inflammatory 266 
bowel diseases under thiopurine therapy remains the best tool to supervise dose management and therapy 267 
response. Further research is necessary to optimize the model structures to make them clinically applicable 268 
and useful.  269 
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Table 1: Descriptive statistics of quantitative clinical and laboratory parameters per observation used 366 
for statistical models1 367 
 Valid N (%) Mean Median σ IQR Min. Max. 
Age [years] 1158 (100%) 38 35 14.4 18 16 81 
BMI [kg/m2] 951 (82%) 23.5 22.5 4 6 14.3 42.3 
Dose [mg] 1056 (91%) 104 100 57.2 100 0 300 
TPMT activity  
[MTG/g Hb/h] 
713 (62%) 52 51 14.3 18 24 86 
Creatinine [μmol/L] 982 (85%) 76 73 20 19 21 235 
Albumin [g/L] 744 (64%) 43 43 3.6 4 27 53 
Bilirubin [μmol/L] 832 (72%) 11 9 7.7 7 1 79 
AST [U/L] 622 (54%) 25 23 14.8 10 9 169 
ALT [U/L] 1024 (88%) 25 19 23.6 14 5 291 
GGT [U/L] 951 (82%) 39 18 109.8 16 2 1696 
ALP [U/L] 939 (81%) 66 58 46.4 27 10 888 
CRP [ng/L] 1024 (88%) 7 2 18.5 4 0.3 278 
Hb [g/dL] 1112 (96%) 13.3 13.3 1.5 2 7.3 17.7 
MCV [fL] 1112 (96%) 92 91 7 9 59 118 
Platelets [103/μL] 1112 (96%) 312 300 95.1 114 74 843 
Leukozytes [103/μL] 1112 (96%) 7 6.6 2.85 3.35 1.8 22.57 
Lymphocytes [103/μL] 1105 (95%) 1.25 1.15 0.67 0.87 0.13 4.93 
Prothrombin time [%] 294 (25%) 102 103 14.2 18 29 127 
Calprotectin [μg/g] 206 (18%) 617 289 1086.6 723 19 10114 
TGN [pmol/8∙108 RBC] 1158 (100%) 340 306 193.8 213 48 1435 
MMP [pmol/8∙108 RBC] 1158 (100%) 1807 763 3127 1690 46 46410 
MMP/TGN [-] 1158 (100%) 6.69 2.66 11.74 5.62 0.08 93.39 
1N: number of observations, σ: standard deviation, IQR: interquartile range, BMI: Body-Mass-Index, TPMT: 368 
Thiopurine methyltransferase activity, AST: Aspartate transaminase, ALT: Alanine transaminase, GGT: 369 
Gamma-glutamyl transpeptidase, ALP: Alkaline phosphatase, CRP: C-reactive protein, Hb: Hemoglobine, 370 
MCV: Mean cellular volume, TGN: 6-thioguanine nucleotides, MMP: 6-methyl-mercaptopurine, RBC: red 371 
blood cells, [31]: Methyl-thioguanine per gram hemoglobine per hour 372 
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Table 2: Adjusted coefficient estimates from best fitting linear mixed models for the prediction of 373 
ln(TGN) and ln(MMP)1 374 
 ln(TGN) ln(MMP) 
slope (b) 95% CI p-value slope (b) 95% CI p-value 
BMI -0.018 -0.04;0.001 0.064    
Dose 0.0004 -0.001;0.001 0.43 0.01 0.009;0.014 <0.001 
Ln(bilirubin) 0.19 0.1;0.29 <0.001 0.43 0.22;0.64 <0.001 
Ln(ALT) -0.13 -0.21;-0.04 0.005 0.47 0.2;0.75 0.001 
Ln(CRP) -0.02 -0.06;0.02 0.322 -0.05 -0.13;0.04 0.294 
Hb -0.07 -0.11;-0.03 0.001 -0.18 -0.27;-0.1 <0.001 
MCV 0.03 0.02;0.04 <0.001 0.03 0.01;0.05 0.002 
Ln(leukocytes) -0.22 -0.36;-0.08 0.003    
Ln(lymphocytes) -0.06 -0.17;0.04 0.231    
Ln(AST)    -0.47 -0.88;-0.06 0.023 
Ln(ALP)    -0.62 -0.98;-0.25 0.001 
AIC 971 1125 
BIC 980 1132 
1TGN: 6-thioguanine nucleotides, CI: Confidence interval, Ln(y): Natural logarithm of y, BMI: Body-Mass-375 
Index, ALT: Alanine transaminase, AST: Aspartate transaminase, CRP: C-reactive protein, Hb: 376 
Hemoglobine, MCV: Mean cellular volume, GEE: General Estimating Equations, π: probability of non-377 
response, ALP: Alkaline phosphatase, TGN: 6-thioguanine nucleotides, AIC: Akaike Information Criterion, 378 
BIC: Bayesan Information Criterion,  379 
14 
 
Table 3: Adjusted coefficient estimates from best fitting multiple GEE to predict  1 380 
 Best fitting GEE 
slope (b) 95% CI p-value 
Albumin -0.64 -0.12;-0.009 0.023 
Ln(ALP) 0.47 -0.19;1.12 0.16 
Ln(CRP) 0.16 0.003;0.32 0.045 
Ln(leukocytes) 1.2 0.63;1.79 <0.001 
Ln(TGN) -0.31 -0.66;0.043 0.085 
QIC 638 
1GEE: General Estimating Equations, π: probability of non-response, CI: Confidence interval, Ln(y): 381 
Natural logarithm of y, ALP: Alkaline phosphatase, CRP: C-reactive protein, TGN: 6-thioguanine 382 
nucleotides, QIC: Quasi-likelihood under the independence model Criterion 383 
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Legend to Figure 1:  384 
Correlation between measured and predicted thiopurine metabolite concentrations  385 
TGN: 6-thioguanine nucleotides, MMP: 6-methyl-mercaptopurine, ln: Natural logarithm. The vertical lines 386 
of dots represent the lower threshold of quantification. Rarely, values below that threshold were 387 
documented in the electronic database. 388 
 389 
Legend to Figure 2:  390 
Receiver operating characteristic (ROC) curve for the model of treatment outcome  391 
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Fig. 2: Receiver operating characteristic (ROC) curve for the model of treatment outcome  394 
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Supplementary information:  
 
Supplementary table 1: Descriptive statistics of qualitative data of patients and observations (numbers 
indicate a positive answer to the question whether the characteristic was present at the time point of 
observation, numbers in brackets are per cent of patients and observations, respectively. “Valid” means 
that information on this characteristic was available in the patient records, “missing” means that 
information was not available).  
Patients     273 Observations    1158 
Sex (valid 273, 0 missing) 
Female    109 (40%*) 
Male    164 (60%) 
 
Diagnosis (valid 273, 0 missing) 
Crohn’s disease   157 (58%) 
 Ulcerative colitis   115 (42%) 
 Indeterminate colitis  1 (0%) 
 
TPMT Genotype (valid 136, 137 missing) 
 Wild type   130 (96%) 
 Mutation    6 (4%) 
 
TPMT Phenotype (valid 135, 138 missing) 
 Low enzyme activity  9 (7%) 
 High/intermediate enzyme acivity 126 (93%) 
 
Mean observations per patient (min; max) 4.2 (1;29) 
Smoking status (valid 829, 329 missing)  
Non-smokers   618 (75%) 
 Smokers   211 (25%) 
Type of thiopurine (valid 1119, 39 missing) 
 Azathioprine   893 (80%) 
 6-mercaptopurine  198 (18%) 
 Thioguanine   22 (2%) 
 None at the time of measurement 6 (0.5%) 
Co-medication** (valid 844, 314 missing) 
 No-comedication   133 (11%) 
 At least one comedication  711 (61%) 
Used drugs (valid, missing) 
 Corticosteroids (772, 386)  361 (47%) 
 Mesalazine (706, 452)  360 (51%) 
 Allopurinol (841, 317)  167 (20%) 
 Calcineurin inhibitors (1124, 34) 17 (1%) 
 TNF inhibitors (1124, 34)  138 (12%) 
Clinical outcome (valid 952, 206 missing) 
 Response/Remission  659 (69%) 
 Non-response   293 (31%) 
TPMT: Thiopurine methyltransferase, min: minimum, max: maximum, IBD: Inflammatory bowel disease, TNF: 
Tumor necrosis factor, **only IBD-related co-medication, *complete table presents valid percentage terms 
 
